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Introduction {#sec1}
============

Mouse embryonic stem cells (ESCs) that lack microRNAs (miRNAs) due to *Dicer1* or *Dgcr8* deficiency do not proliferate well and display severe differentiation defects ([@bib9], [@bib19], [@bib32]). The most highly expressed miRNAs in mouse ESCs belong to the miR-290 family, a cluster of nine miRNAs (also referred to as miR-290∼295), six of which share the same "seed" sequence ([@bib7]). The orthologous human families are miR-302 and miR-371 ([@bib29]). In mice, the miR-290 cluster is transcribed from a single locus on chromosome 7 by the core ESC transcriptional network ([@bib14]) and can rescue defective proliferation in ESCs that lack miRNAs ([@bib32]). While the importance of the miR-290 family is clear, how it contributes to the gene expression program in ESCs is not fully known.

The *Hox* family of transcription factors governs the anterior to posterior axial body plan of vertebrates ([@bib23]). In mouse and human, the *Hox* genes are found in four chromosomal clusters (A, B, C, and D). *Hox* genes are transcriptionally inactive in ESCs due to the action of Polycomb repressive complexes (PRC) ([@bib4], [@bib10]), but the role, if any, of miRNAs in this process has not been established.

Polycomb group (PcG) proteins are transcriptional repressors that regulate embryonic development and function in ESC pluripotency and induced pluripotent stem cell (iPSC) generation ([@bib2], [@bib3], [@bib21]). There are two Polycomb complexes, PRC1 and PRC2, that differ biochemically ([@bib6]). PRC2 catalyzes the trimethylation of histone H3K27 (H3K27me3), which is recognized by PRC1, although PRC1 can be recruited to chromatin independently of PRC2 and H3K27me3 ([@bib27]). Overall, despite extensive study, it remains unclear how Polycomb repressive chromatin domains are established in ESCs and reversed during development to allow the expression of differentiation genes.

Both PcG proteins and Dicer are required for ESC proliferation, pluripotency, and differentiation and play key roles in development, but the interplay between the two has not been studied. We observed that in DCR^−/−^ ESCs, *Hox* genes, which are Polycomb targets, were upregulated, which in turn led to the finding that miR-290 is required for efficient gene repression involving Polycomb targeting.

Results {#sec2}
=======

Collectively, miR-290 miRNAs with the seed sequence 5′-AAGUGC-3′ account for ∼70% of mature miRNAs expressed in ESCs, and these are undetectable in DCR^−/−^ ESCs by Nanostring analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib5], [@bib7]). To determine the role of the miR-290 family in ESC gene regulation, we transfected a synthetic miR-291a-3p mimic (abbreviated as miR-291 hereafter) into DCR^−/−^ ESCs and performed transcriptome sequencing analysis (RNA-seq). Our RNA-seq analysis revealed that genes belonging to the *Hoxa*, *Hoxb*, and *Hoxd* gene clusters were among the most differentially expressed in DCR^−/−^ ESCs ([Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). Transfection of miR-291 dramatically restored *Hox* gene silencing ([Figure 1](#fig1){ref-type="fig"}A). In contrast, previously characterized miR-290 targets, such as *Cdkn1a* and *Rbl2* ([@bib32]) were modestly regulated ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B).

To demonstrate that miR-291 transfection mimics physiological levels, we measured its relative expression by qRT-PCR. miR-291 levels in transfected DCR^−/−^ ESCs were 6-fold higher than in untransfected DCR^fl/fl^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Considering that miR-291a is one of six miRNAs with the same seed sequence, some of which are more highly expressed in ESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}A), the miR-291 concentration after transfection in DCR^−/−^ ESCs was actually at or below endogenous aggregate levels for the whole miR-290 family. Thus the observed repression of *Hox* genes was not due to overexpression of miR-291. In addition, transfection of miR-291 had little effect on the transcriptome of DCR^fl/fl^ cells---only four genes exhibited a greater than 2-fold change (data not shown). Also, the only motif enriched in the 3′ UTRs of transcripts regulated by miR-291 by Sylamer analysis ([@bib31]) was complementary to the miR-290 seed sequence, thereby indicating specificity.

We confirmed the suppression of representative *Hox* genes, including *Hoxa7*, *Hoxa10*, *Hoxb9*, and *Hoxd9* upon miR-291 transfection by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}C). Similarly, transfection of miR-294, another member of the miR-290 family, potently reduced *Hox* gene transcripts ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Thus, the miR-290 family is a regulator of *Hox* gene expression in ESCs.

*Hox* genes are activated during ESC differentiation. However, *Hox* gene overexpression did not appear to be the consequence of a broad program of differentiation of DCR^−/−^ ESCs. For example, we did not observe downregulation of the core pluripotency factors *Oct4*, *Sox2*, *Klf4*, and *Nanog* nor upregulation of differentiation markers such as *Brachyury*, *Fgf5*, *Gata4*, and *Gata6* ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}).

Since RNA-seq and qRT-PCR analyses cannot provide information at the single-cell level, we performed RNA fluorescence in situ hybridization (RNA-FISH) for *Hoxa9* to assess whether the observed upregulation was due to a few cells expressing high levels of *Hox* transcripts or a general characteristic of DCR^−/−^ ESCs. The RNA-FISH analysis showed more *Hoxa9* transcripts in the majority of DCR^−/−^ ESCs, while the housekeeping gene *Hprt* was not differentially expressed ([Figure 2](#fig2){ref-type="fig"}B). The DAPI nuclear signal demarcates individual cells.

To exclude that *Hox* derepression was due to prolonged culture of DCR^−/−^ ESC clones, we deleted Dicer acutely using a tamoxifen-inducible Cre DCR^fl/fl^ ES cell line (DCR^fl/fl^; R26CreERT2) ([@bib20]). Three days after tamoxifen (4OHT) addition, DICER protein was dramatically reduced, and 9 days later ARGONAUTE2 (AGO2), which is destabilized in the absence of mature miRNAs ([@bib15]), was also decreased ([Figure 2](#fig2){ref-type="fig"}C inset), while *Hoxa10* and *Hoxd9* transcripts were upregulated.

To test whether miR-291 regulated *Hox* mRNA stability, we inserted the 3′ UTR of *Hoxa9* and *Hoxd10* downstream of a luciferase reporter. We observed no effect on luciferase expression when *Hox* reporter vectors were cotransfected with miR-291 in DCR^−/−^ ESCs in contrast to the observed repression when bona fide direct targets such as *Cdkn1a* and *Lats2* 3′ UTRs were tested ([Figure 2](#fig2){ref-type="fig"}D). Cotransfection with miR-293 (a non-"seed"-containing miRNA from the miR-290 cluster) was used as a negative control. These observations suggest that the effect of miR-291 on *Hox* genes is indirect and likely transcriptional; we therefore performed qRT-PCR for *Hoxa9* and *Hoxd10* using intronic primers. Unspliced primary transcripts, a proxy of ongoing transcription, were upregulated in DCR^−/−^ ESCs ([Figure 2](#fig2){ref-type="fig"}E). In addition, RNA polymerase (POL) II occupancy at *Hox* gene promoters was higher in DCR^−/−^ compared to DCR^fl/fl^ ESCs ([Figure 2](#fig2){ref-type="fig"}F). Thus, the increased *Hox* gene expression appeared to be due to transcriptional regulation.

We next examined how miRNAs could regulate *Hox* gene transcription. In ESCs, *Hox* gene promoters are bivalent ([@bib2], [@bib3]), with both activating and repressive histone H3 modifications at lysines 4 and 27 (H3K4me3 and H3K27me3, respectively), but are maintained transcriptionally silent by PcG proteins. Thus, we performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) to determine the localization of the core PRC2 components SUZ12 and JARID2 as well as the H3K27me3 mark catalyzed by this holoenzyme. Using ChIP-seq, and ChIP-qPCR for validation, we found that SUZ12, JARID2, and H3K27me3 were all reduced at *Hox* gene promoters in DCR^−/−^ ESCs ([Figures 3](#fig3){ref-type="fig"}A and 3B). The *Lin28a* promoter, which is not a Polycomb target, was used as a negative control. We also observed a reduction in the association of the PRC1 subunit RING1b at *Hox* loci ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

Furthermore, we observed a global reduction in Polycomb at sites throughout the genome. In the absence of Dicer, there was a marked reduction of SUZ12, JARID2, and H3K27me3 at transcriptional start sites (TSSs) ([Figure 3](#fig3){ref-type="fig"}C). To assess the impact of reduced Polycomb accumulation on the transcriptome of DCR^−/−^ ESCs, we analyzed differentially expressed genes and found there was a significant enrichment for SUZ12 targets in the genes upregulated in DCR^−/−^ ESCs ([Figure 3](#fig3){ref-type="fig"}D). However, not all PRC2 targets with reduced JARID2, SUZ12, and H3K27me3 were transcriptionally upregulated ([Figures S3](#mmc1){ref-type="supplementary-material"}D and [S4](#mmc1){ref-type="supplementary-material"}D). SUZ12, JARID2, EED, and EZH2 protein levels were not decreased nor were mRNA levels for other PcG proteins ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}C). Thus, it seems that deletion of *Dicer1* affects the targeting of PcG proteins to cognate genomic locations rather than the expression levels of PcG proteins.

Since *Hox* genes are prototypical PcG targets in many organisms ([@bib3], [@bib11]), we focused on their regulation as a reflection of overall PcG function. We found that miR-291 significantly increased Suz12 binding at the *Hoxa10* and *Hoxd9* TSSs in DCR^−/−^, but not in DCR^fl/fl^ ESCs ([Figure 3](#fig3){ref-type="fig"}F). Moreover, miR-291 transfection in DCR^−/−^ ESCs significantly reduced Suz12 target gene transcripts ([Figure 3](#fig3){ref-type="fig"}G).

To further investigate the mechanism of miR-291 regulation of PcG recruitment at TSSs and *Hox* gene repression, we examined the differential expression of candidate regulatory genes from RNA-seq analyses. Interestingly, many Trithorax group genes, which are known antagonists of Polycomb, such as mixed lineage leukemia (*Mll*) were upregulated in DCR^−/−^ ESCs and reduced upon miR-291 transfection ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Since we observed no increase in H3K4me3, catalyzed by MLL proteins, at *Hox* loci ([Figure S4](#mmc1){ref-type="supplementary-material"}B) or globally ([Figure S4](#mmc1){ref-type="supplementary-material"}C), MLL proteins, despite their potentially important upregulation, are not likely responsible for antagonizing PRC recruitment in DCR^−/−^ ESCs. We also investigated other prominently deregulated genes, such as the histone acetyltransferase Kat2b and Mllt6, which probably helps catalyze H3K79 methylation ([@bib18]). However, inhibition by garcinol of Kat2b or knockdown of Mllt6 did not restore *Hox* gene repression (data not shown).

However, we discovered that miR-291 regulated another Trithorax group protein, the H3K36 methyltransferase Ash1l. It was recently reported that H3K36me3 deposition at *Hox* loci occurs independently of transcription via the action of ASH1L and is sufficient to evict Polycomb ([@bib16]). We observed that *Ash1l* transcripts and protein were suppressed by miR-291 ([Figures 4](#fig4){ref-type="fig"}A and 4D). Since there is a predicted miR-290 site in the 3′ UTR of *Ash1l* ([@bib12]), we cloned it into a luciferase reporter vector and assessed its activity upon miR-291 cotransfection. We found that the *Ash1l* 3′ UTR decreased luciferase levels when cotransfected with miR-291 ([Figure 4](#fig4){ref-type="fig"}B). ASH1L was also significantly enriched at *Hox* coding regions in DCR^−/−^ ESCs by ChIP ([Figure 4](#fig4){ref-type="fig"}C). We then tested whether *Ash1l* knockdowns could silence *Hox* genes in the absence of Dicer. Although the *Ash1l* knockdown was partial, it significantly reduced *Hoxa10* and *Hoxd9* expression in DCR^−/−^ ESCs ([Figures 4](#fig4){ref-type="fig"}D and 4E). Notably, the effect of *Ash1l* knockdown was less dramatic than usually observed with miR-291, which could reflect either the partial knockdown or the possibility of additional miR-291 targets. Since miRNAs usually target a large number of genes to synergistically induce desired cellular phenotypes, it is likely that a combination of factors, including Ash1l, leads to transcriptional derepression and Polycomb eviction at *Hox* genes and other Polycomb sites.

Discussion {#sec3}
==========

Dicer is essential for the ESC phenotype, although expression of the core pluripotency factors is maintained in DCR^−/−^ ESCs, indicating that miRNAs may control additional determinants of pluripotency. We found that genes associated with ESC differentiation, specifically the *Hox* family, were overexpressed in DCR^−/−^ ESCs. First, we observed that *Hox* genes were regulated by miR-290, the most abundantly expressed miRNA family in undifferentiated ESCs. Second, we could attribute this effect to reduced localization of PRC2. This is important because PcG proteins maintain ESCs in a pluripotent state by silencing *Hox* and other "bivalent" differentiation genes primed for transcription ([@bib2], [@bib3]). Loss of Dicer altered PRC2 recruitment throughout the genome, illustrating the crucial role of miRNAs in governing the targeting of this silencing complex. Consistently, a significant number of PcG target genes were transcriptionally activated in DCR^−/−^ ESCs ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}D). However, some genes lost Polycomb binding but were not transcriptionally activated ([Figures S3](#mmc1){ref-type="supplementary-material"}D and [S4](#mmc1){ref-type="supplementary-material"}D). Hence, PRC removal from chromatin is not always a secondary effect of transcriptional activation of differentiation genes in DCR^−/−^ ESCs ([@bib26]). In fact, there is only 20% overlap of genes activated upon Dicer deletion and retinoic-acid-induced differentiation, and most of these genes are Polycomb targets ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Moreover, we found that reduction of PcG proteins at genomic loci could not be attributed to changes in the expression levels of PRC1 and PRC2 subunits ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}C). Rather, miR-290 members regulate the targeting of PRC1 and PRC2 to appropriate loci in ESCs to maintain their "stemness."

The miR-290 cluster has been previously implicated in regulation of de novo methyltransferases (Dnmts) ([@bib28]), and DNA methylation may affect PcG localization ([@bib25]). It will be interesting to see if the observed reduction in Polycomb binding is partially due to loss of proper DNA methylation in DCR^−/−^ ESCs and redistribution of PRC components across the genome.

We found that miR-291 repressed Ash1l, which can activate *Hox* genes by evicting Polycomb during differentiation ([@bib16], [@bib30]). *Ash1l* is a predicted target of miR-291, which we validated using reporter assays. We observed that knockdown of *Ash1l* reduced *Hox* gene expression in DCR^−/−^ ESCs, suggesting that reduction of H3K36 methylation is sufficient to partially suppress *Hox* gene transcription. Thus, our data reveal a circuit of miRNA control of ESC gene expression through *Ash1l* and targeting of PcG proteins.

It has been reported that the miR-290 family enhances generation and quality of mouse and human iPS cells, but the mechanism is not fully understood ([@bib1], [@bib8], [@bib13], [@bib17]). PRC2 is also required for reprogramming ([@bib21], [@bib24]), and similar to DCR^−/−^ ESCs, PRC2 mutant ESCs fail to differentiate ([@bib22]). This could imply that these two phenotypes may be related, since we show that PcG targeting is influenced by miR-290 miRNAs in ESCs. Thus, this regulatory mechanism may affect not only *Hox* genes but also other factors important for pluripotency. It will be interesting to explore whether there is a broader role of this gene regulatory circuit in pluripotency and differentiation in various types of stem cells and cancer.

Experimental Procedures {#sec4}
=======================

Cell Culture and Transfections {#sec4.1}
------------------------------

All animal work was done in accordance with the guidelines of the Institutional Animal Care and Use Committee. DCR^fl/fl^ ESCs were derived from days post-coitum (DPC) 3.5 embryos. DCR^−/−^ clones were isolated after Adeno-Cre (Harvard Gene Therapy). For acute Dicer deletion, cells were treated with 2.5 μM of 4OHT (Sigma). Prior to transfections, harvesting of cells for RNA, protein, or ChIP, mouse embryonic fibroblasts (MEFs) were removed using MEF removal microbeads (Miltenyi Biotech). For detailed description, please see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Protein Analyses, ChIP, and ChIP-Seq {#sec4.2}
------------------------------------

ChIP was performed according to published protocols. A detailed description is provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. All P values were calculated with an unpaired Student's t test unless otherwise stated. ^∗^ p \< 0.05; ^∗∗^ \< 0.01; ^∗∗∗^ p \< 0.001.

Western blotting was performed as previously described. Western blots (WBs) for PRC2 components were analyzed using the Li-Cor imaging system and software.

RNA Analyses {#sec4.3}
------------

RNA was prepared with Trizol (Invitrogen) or RNAzol (MRC) reagent according to the manufacturer's instructions. All primers were designed using the Primer 3 software (Steve Rozen, Helen J. Skaletsky, <http://biotools.umassmed.edu/bioapps/primer3_www.cgi>), and sequences are provided in [Table S2](#mmc1){ref-type="supplementary-material"}. RNA-seq libraries were prepared using the TruSeq Stranded mRNA Sample Prep Kit or TruSeq RNA Sample Preparation Kit v2 and analyzed on a GAIIx genome analyzer (Illumina). For RNA FISH, labeled probes (Quantigene RNA VIEW ISH probes) were purchased from Panomics and used according to the manufacturer's instructions (see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). miRNA abundance was quantified with the nCounter miRNA Expression Assay (Nanostring Technologies) or with individual Taqman miRNA assays (ABI).

Accession Numbers {#app1}
=================

The accession number for the RNA-seq and ChIP-seq data reported in this paper is NCBI GEO: [GSE60397](ncbi-geo:GSE60397){#intref0015}.
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![miR-291 Restores *Hox* Gene Repression in DCR^−/−^ ESCs\
(A) Genome browser screenshot of the RNA-seq reads aligning to the *Hoxa* and *Cdkn1a* loci in DCR^fl/fl^ and DCR^−/−^ ESCs ± miR-291.\
(B) Sylamer analysis of motifs enriched in the 3′ UTRs of differentially expressed mRNAs after transfection with miR-291. Vertical red dashed lines mark the cut-off for log~2~-fold change of 2, 1, and 0 as indicated.\
(C) qRT-PCR for representative *Hox* genes, in DCR^fl/fl^ and DCR^−/−^ cells before and after transfection with miR-291. Each bar represents the mean ± SD of three independent experiments.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Homeobox Genes Are Transcriptionally Upregulated in DCR^−/−^ ESCs\
(A) Scatterplot of normalized read values of DCR^fl/fl^ versus DCR^−/−^ ESCs from an RNA-seq experiment. Highlighted are genes belonging to the *Hox* clusters, the core pluripotency factors *Oct4*, *Sox2*, *Klf4*, *Nanog*, and *Lin28a* and two miR-290 targets, *Cdkn1a* and *Lats2*. Red dashed lines indicate the 2-fold change cut-off for differentially expressed genes (dots in red).\
(B) RNA-FISH for *Hoxa9* (green) and *Hprt* (red) in DCR^fl/fl^ and DCR^−/−^ ESCs (scale bar, 10 μm). Nuclei are counterstained by DAPI.\
(C) qRT-PCR for representative *Hox* genes in DCR^fl/fl^;R26CreERT2 cells with or without the addition of tamoxifen (4OHT). (Bars represent mean ± SD of three independent experiments.) Inset shows western blot analysis of DICER and AGO2 protein levels. ACTIN is shown as a loading control.\
(D) Normalized luciferase levels after transfection of DCR^−/−^ ESCs with indicated vectors ± miR-291 or miR-293. Values were normalized to the no miRNA control. Bars represent mean of two (Hoxa10-UTR and Hoxd9-UTR) or one (Cdkn1a and Lats2) independent experiments.\
(E) qRT-PCR for representative *Hox* genes using intronic primers.\
(F) ChIP-qPCR of RNA POL II at *Hoxa10*, *Hoxd9*, and *Lin28a* promoters (bars represent mean ± SD of eight independent experiments). Data are represented as fold change of DCR^−/−^ over DCR^fl/fl^ signal.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Defect in PcG Protein Recruitment in DCR^−/−^ ESCs.\
(A) ChIP-qPCR analysis of SUZ12, JARID2, H3K27me3 at *Hoxa10* and *Hoxd9* promoters and the *Lin28a* promoter as a control (bars represent mean ± SD of at least five independent experiments). Data are represented as fold change of DCR^fl/fl^ over DCR^−/−^ signal.\
(B) Genome browser screenshot of the reads aligning to the *Hoxd* locus after ChIP with anti-SUZ12, anti-JARID2, or anti-H3K27me3 antibodies.\
(C) Line plot depicts distribution of H3K27me3 (left), SUZ12 (middle), and JARID2 (right) localization at TSS ± 5 kb of all RefSeq genes.\
(D) Cumulative fraction plot of the total number of expressed genes (black line) and genes that have a SUZ12 peak in DCR^fl/fl^ ESCs (green line) sorted by log~2~-fold change of the reads in DCR^fl/fl^ versus DCR^−/−^ ESCs. P value was calculated using a Kolmogorov-Smirnov test.\
(E) Western blot showing the levels of EZH2, SUZ12, JARID2, and EED. Numbers below each lane represent the signal of each band normalized to the signal from tubulin. The normalized signal from the DCR^fl/fl^ lysates is set to 1.\
(F) ChIP-qPCR for SUZ12 in DCR^fl/fl^ and DCR^−/−^ cells before and after transfection with miR-291. Bars represent mean ± SD of three independent experiments.\
(G) Same as (D), but the log~2~-fold change of the reads in DCR^−/−^ cells ± miR-291 is plotted. P value was calculated using a Kolmogorov-Smirnov test.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Histone Methyltransferase Ash1l Is a Target of miR-291 and Regulates *Hox* Gene Expression\
(A) Relative expression of *Ash1l* in DCR^fl/fl^ and DCR^−/−^ ESCs ± miR-291.\
(B) Normalized luciferase levels after transfection of DCR^−/−^ ESCs with indicated vectors ± miR-291. Values were normalized to the no miRNA control. Bars represent mean ± SD of three independent experiments.\
(C) ChIP-qPCR analysis of ASH1L enrichment at indicated loci. Data are represented as fold change of DCR^−/−^ over DCR^fl/fl^ signal.\
(D) Relative expression of *Hoxa10*, *Hoxd9*, and *Ash1l* in DCR^−/−^ ESCs after transfection with the indicated miRNA or siRNA. Bars represent mean ± SD of three independent experiments. Data are represented as fold change compared to DCR^−/−^ ESCs.\
(E) Western blot showing the levels of ASH1L in DCR^fl/fl^ and DCR^−/−^ ESCs mock transfected or transfected with miR-291 or siRNAs targeting *Ash1l* (siAsh1l). Numbers below each lane indicate the signal of each band normalized to the signal from HSP90. The normalized signal for DCR^fl/fl^ is set to 1.\
(F) Schematic model of miR-290 regulation of PcG targeting and Ash1l.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
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